metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
endometrial cancer endometrial cancer
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1			-
	dostarlimab plus soC vs. placebo plus SoC	2			-
	durvalumab plus olaparib plus SoC vs. placebo plus SoC	1			-
	durvalumab plus SoC vs. placebo plus SoC	1			-
	pembrolizumab plus SoC vs. placebo plus SoC	2	-	-	-
versus Standard of Care (SoC)
	avelumab plus SoC vs. Standard of Care (SoC)	1			-
	pembrolizumab plus lenvatinib vs. Standard of Care (SoC)	2			-
endometrial cancer - (neo)adjuvant (NA) endometrial cancer - (neo)adjuvant (NA)